Search Results - "Mallon, Patrick WG"

Early inflammatory profiles predict maximal disease severity in COVID-19: An unsupervised cluster analysis by Kenny, Grace, Saini, Gurvin, Gaillard, Colette Marie, Negi, Riya, Alalwan, Dana, Garcia Leon, Alejandro, McCann, Kathleen, Tinago, Willard, Kelly, Christine, Cotter, Aoife G., de Barra, Eoghan, Horgan, Mary, Yousif, Obada, Gautier, Virginie, Landay, Alan, McAuley, Danny, Feeney, Eoin R., O'Kane, Cecilia, Mallon, Patrick WG

“…The inflammatory changes that underlie the heterogeneous presentations of COVID-19 remain incompletely understood. In this study we aimed to identify…”
Get full text

Weight gain before and after switch from TDF to TAF in a U.S. cohort study by Mallon, Patrick WG, Brunet, Laurence, Hsu, Ricky K, Fusco, Jennifer S, Mounzer, Karam C, Prajapati, Girish, Beyer, Andrew P, Wohlfeiler, Michael B, Fusco, Gregory P

“…Introduction Although weight gain has been reported with the use of integrase strand transfer inhibitors (InSTI), concurrent use of tenofovir alafenamide (TAF)…”
Get full text

Obesity is associated with higher levels of circulating cytokines involved in the development of cardiovascular disease in people living with HIV by Savinelli, Stefano, McGettrick, Pádraig, Garcia Leon, Alejandro A, Tinago, Willard, Haran, Emma, Barco, Elena Alvarez, Landay, Alan L, Mallon, Patrick Wg, Feeney, Eoin R

“…Obesity is increasingly described in people living with HIV (PLWH), but its impact on immune activation and inflammation in HIV is still poorly characterised…”
Get full text

Associations Between Widespread Pain and Sleep Quality in People With HIV by Sabin, Caroline A., Harding, Richard, Doyle, Nicki, Redline, Susan, de Francesco, Davide, Mallon, Patrick W. G., Post, Frank A., Boffito, Marta, Sachikonye, Memory, Geressu, Adam, Winston, Alan, Kunisaki, Ken M.

“…BACKGROUND:We investigate the association of widespread pain with sleep quality among people with HIV and HIV-negative controls. SETTING:UK-based cohort…”
Get full text

Relative contribution of HIV infection, demographics and body mass index to bone mineral density by Cotter, Aoife G, Sabin, Caroline A, Simelane, Sibongile, Macken, Alan, Kavanagh, Eoin, Brady, Jennifer J, McCarthy, Geraldine, Compston, Juliet, Mallon, Patrick W G

“…Low bone mineral density (BMD) is common in HIV-positive patients, although the role played by HIV infection versus sociodemographic and metabolic factors…”
Get full text

Predictors of longitudinal change in bone mineral density in a cohort of HIV-positive and negative patients by Tinago, Willard, Cotter, Aoife G, Sabin, Caroline A, Macken, Alan, Kavanagh, Eoin, Brady, Jennifer J, McCarthy, Geraldine, Compston, Juliet, Mallon, Patrick W.G

“…OBJECTIVE:Although low bone mineral density (BMD) is prevalent in HIV, changes in BMD over time remain unclear. We aimed to compare rates of, and factors…”
Get full text

Development of a risk assessment profile tool to determine appropriate use of SARS-CoV-2 rapid antigen detection tests for different activities and events in Ireland, since October 2021 by Mallon, Patrick Wg, Horgan, Mary, McAloon, Conor G, Lunn, Peter D, Little, Julian, Beck, Andrew, Bennett, Alexandria, Shaver, Nicole, Conway, Aileen, O'Regan, Rhea, Whelan, Barbara

“…We describe the development of a risk assessment profile tool that incorporates data from multiple domains to help determine activities and events where rapid…”
Get full text

Correlation between computerised and standard cognitive testing in people with HIV and HIV-negative individuals by De Francesco, Davide, Underwood, Jonathan, Anderson, Jane, Boffito, Marta, Post, Frank A., Sachikonye, Memory, Mallon, Patrick W.G., Haddow, Lewis, Vera, Jaime H., Kunisaki, Ken M., Sabin, Caroline A., Winston, Alan

“…We investigated the correlations and agreement between cognitive assessments made using a computerised (CogState™, six domains) and a standard pen-and-paper…”
Get full text

HIV and HAART-Associated Dyslipidemia by Feeney, Eoin R, Mallon, Patrick W G

“…Effective highly active antiretroviral therapy (HAART) for human immunodeficiency virus-1 (HIV) infection has led to marked improvement in life-expectancy for…”
Get full text

HIV and bone mineral density by Mallon, Patrick WG

“…PURPOSE OF REVIEWThis review details the clinical aspects and pathogenesis of low bone mineral density (BMD) in HIV, discusses broad management issues and…”
Get full text

Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy by MALLON, Patrick W. G, MILLER, John, COOPER, David A, CARR, Andrew

“…Little prospective data are published on the natural history of HIV-associated lipodystrophy (HIVLD) in individuals beginning their first antiretroviral…”
Get full text

The rate of bone loss slows after 1-2 years of initial antiretroviral therapy: final results of the START bone mineral density substudy by Carr, Andrew, Grund, Birgit, Schwartz, Ann V, Avihingsanon, Anchalee, Badal-Faesen, Sharlaa, Bernadino, Jose I, Estrada, Vicente, Rosa, Alberto La, Mallon, Patrick WG, Pujari, Sanjay, White, David, Engen, Nicole Wyman, Ensrud, Kristine, Hoy, Jennifer F

Get full text

Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study by Cotter, Aoife G, Vrouenraets, Saskia M. E, Brady, Jennifer J, Wit, Ferdinand W, Fux, Christoph A, Furrer, Hansjakob, Brinkman, Kees, Sabin, Caroline A, Reiss, Peter, Mallon, Patrick W. G

“…Context: In virologically suppressed, antiretroviral-treated patients, the effect of switching to tenofovir (TDF) on bone biomarkers compared to patients…”
Get full text

Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy by Martin, Allison, Moore, Cecilia, Mallon, Patrick W.G., Hoy, Jennifer, Emery, Sean, Belloso, Waldo, Phanuphak, Praphan, Ferret, Samuel, Cooper, David A., Boyd, Mark A.

“…OBJECTIVE:To compare changes over 48 weeks in bone mineral density (BMD) between participants randomized to lopinavir/ritonavir (LPV/r) + raltegravir (RAL) or…”
Get full text

Platelet function and HIV: a case-control study by SATCHELL, Claudette S, COTTER, Aoife G, O'CONNOR, Eileen F, PEACE, Aaron J, TEDESCO, Anthony F, CLARE, Andrew, LAMBERT, John S, SHEEHAN, Gerard J, KENNY, Dermot, MALLON, Patrick W. G

“…Cardiovascular disease and myocardial infarction are of increasing concern in HIV-infected populations. Although platelets mediate arterial thrombosis, central…”
Get full text

Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study by Mallon, Patrick W G, Miller, John, Kovacic, Jason C, Kent-Hughes, Julia, Norris, Richard, Samaras, Katherine, Feneley, Michael P, Cooper, David A, Carr, Andrew

“…To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in…”
Get full text

A randomized, controlled study exploring factors associated with decision to undergo HIV screening by O’Connor, Gerard, Ni Flaitheartaigh, Ailbhe, Lacey, Aoife, O’Halloran, Jane, Brazil, Eamon, Calderon, Yvette, Mallon, Patrick WG

Get full text

High-density lipoprotein levels and 10-year cardiovascular risk in HIV-1-infected patients by COTTER, Aoife G, SATCHELL, Claudette S, O'HALLORAN, Jane A, FEENEY, Eoin R, SABIN, Caroline A, MALLON, Patrick W. G

“…We aimed to determine the contribution of high-density lipoprotein cholesterol (HDL-c) to cardiovascular disease (CVD) risk in a cohort of HIV-infected…”
Get full text

Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy by Winston, Alan, Bloch, Mark, Carr, Andrew, Amin, Janaki, Mallon, Patrick W. G., Ray, John, Marriott, Debbie, Cooper, David A., Emery, Sean

“…Objectives: Atazanavir is a recently approved HIV protease inhibitor (PI). As with other PIs, careful attention to potential pharmacokinetic drug interactions…”
Get full text

Therapeutic approaches to combating lipoatrophy: do they work? by Martin, Allison, Mallon, Patrick W. G.

“…Therapeutic strategies for combating HIV-associated lipodystrophy, and lipoatrophy in particular, have been a major focus of HIV clinical research. The initial…”
Get full text